跳至主要内容
临床试验/NCT05494775
NCT05494775Unknown不适用

Effects of Corona Virus Pandemic on Intravitreal Injections

Benha University1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2019年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
250
试验地点
1
主要终点
Visual acuity

研究概览

简要总结

During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.

详细描述

The corona virus pandemic may affects patients regular visits to ophthalmic clinic, we aim to study the sequel of the pandemic on intravitreal injections results in diabetic macular edema, wet age related macular degenerations, myopic choroidal new vascularization, and proliferative diabetic retinopathy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with the following conditions (diabetic macular edema, wet age related macular degeneration, myopic choroidal new vascularization and retinal vein occlusion complicated with macular edema).

排除标准

  • patients that are known to have hypersensitivity to Anti-VEGFs.

研究组 & 干预措施

Diabetic macular edema

Active Comparator

Cases with diabetic macular edema that are prepared for intravitreal injection of anti-vascular endothelial growth factors.

干预措施: Anti-vascular endothelial growth factors (Anti-VEGFs) (Drug)

Wet age related macular edema

Active Comparator

Cases with wet age related macular degenerations that are prepared for intravitreal injection of anti-vascular endothelial growth factors.

干预措施: Anti-vascular endothelial growth factors (Anti-VEGFs) (Drug)

Retinal vein occlusion

Active Comparator

Cases with macular edema secondary to retinal vein occlusion that are prepared for intravitreal injection of anti-vascular endothelial growth factors.

干预措施: Anti-vascular endothelial growth factors (Anti-VEGFs) (Drug)

Myopic choroidal new vascularization

Active Comparator

Cases with myopic choroidal new vascularization that are prepared for intravitreal injection of anti-vascular endothelial growth factors.

干预措施: Anti-vascular endothelial growth factors (Anti-VEGFs) (Drug)

结局指标

主要结局

Visual acuity

时间窗: Baseline and monthly after injection till one year of follow-up

Assessing the changes in best corrected visual acuity in logMAR unit measured by snellen chart.

次要结局

  • Central subfield thickness(Baseline and monthly after injection till one year of follow-up)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed Abdelshafy

Associate professor of Ophthalmology

Benha University

研究点 (1)

Loading locations...

相似试验